Generalized hypopigmentation due to imatinib: A fairness boon? [2]

Indian Journal of Dermatology, Venereology and Leprology

Volumn 71, Issue 1, 2005, Pages 45-46

  Sharma, Atul ^a   Vora, Amish ^a   Bhutani, Manisha ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ALOPECIA; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL OBSERVATION; DERMATITIS; DRY SKIN; EDEMA; ELECTRON MICROSCOPY; ENZYME ASSAY; ERYTHEMA; EXPERIENCE; FACE EDEMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; INTERVIEW; LETTER; MELANOSOME; NIGHT SWEAT; PHOTOSENSITIVITY; PRURITUS; QUANTITATIVE ANALYSIS; SKIN BIOPSY; SKIN PIGMENTATION;

EID: 14844331124     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.13788     Document Type: Letter

References (5)

1. GlivecFNx01 (imatinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; 2001.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
3. Luo D, Chen H, Searles G, Jimbow K. Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/ SCF-R. Melanoma Res 1995;5:303-9.
4. Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-Kit receptor in hypomelanosis: A comparative study between piebaldism, nevus depigmentosus and vitiligo. Br J Dermatol 1995;132:182-9.
5. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.